Breast Cancer Update Welcome to the monthly Cancer Health Breast Cancer email update. We bring you all our breast cancer coverage in one convenient email. To change your preferences, please visit your personal preferences page link at the bottom of this email. Breast Cancer Update FDA Approves Trodelvy for Most Common Type of Metastatic Breast Cancer The antibody-drug conjugate is now approved for patients with hormone receptor-positive/HER2-negative or triple-negative breast cancer. WHO Launches New Roadmap on Breast Cancer In most countries, breast cancer is the first or second leading cause of cancer deaths among women. FDA Approves Orserdu for Certain Patients With HER2-Negative Advanced Breast Cancer Orserdu (elacestrant) is the first treatment for people with ESR1 mutations, which can drive resistance to standard hormone therapy. Breast Cancer Vaccine Looks Promising in Early Study The experimental vaccine trains the immune system to recognize HER2 proteins on breast tumors. A Safer, Better Treatment Option for Some Younger Women with Breast Cancer Women who received a combination of Kisqali and hormone therapy lived twice as long without their cancer getting worse. Advertisement How I Filled My Creative Cup in 2022… …and what I list as my top three priorities of 2023. Exercise During Chemotherapy Is Safe, Feasible and Effective People who began an exercise program after completing chemotherapy saw similar but delayed benefits. Managing Stress When You Have Cancer A cancer diagnosis can cause a lot of stress. There are many ways to reduce stress, so make time to tend to your whole being—body, mind and soul. Science News Vitamin D Supplements May Reduce Melanoma Risk Colonoscopy Rates Are Low Following Positive Stool Tests for Colon Cancer Marijuana Use Not Linked to Worse Outcomes After a Liver Transplant FDA Approves Trodelvy for Most Common Type of Metastatic Breast Cancer Blog: National Cancer Institute Help Desk for Oncologists Treating a Rare Leukemia Pays Big Dividends Brukinsa’s Approval Improves Targeted Treatment for Leukemia Doing More—Together—to End Cancer as We Know It Trial Suggests Expanded Role for Blinctyo in Treating Leukemia Science News Vitamin D Supplements May Reduce Melanoma Risk Colonoscopy Rates Are Low Following Positive Stool Tests for Colon Cancer Marijuana Use Not Linked to Worse Outcomes After a Liver Transplant FDA Approves Trodelvy for Most Common Type of Metastatic Breast Cancer Blog: National Cancer Institute Help Desk for Oncologists Treating a Rare Leukemia Pays Big Dividends Brukinsa’s Approval Improves Targeted Treatment for Leukemia Doing More—Together—to End Cancer as We Know It Trial Suggests Expanded Role for Blinctyo in Treating Leukemia

You are receiving this email because you opted in at one of our websites. At your request, this message was sent to newsletter@newslettercollector.com by update@cancerhealth.com. Please remember to add update@cancerhealth.com to your email address book, so that these updates aren't blocked as spam.

To change your subscription information and preferences, please visit your personal preferences page. Or you can unsubscribe completely from this list.

To forward this message, please do not use the forward button of your email application, because this message was made specifically for you only. Instead use the forward page in our newsletter system.

Did you receive this email from a friend? You can subscribe and you will receive our next newsletter directly to your inbox.

Our mailing address is: